

RESPONSE TO ELECTION OF SPECIES REQUIREMENT
AND PRELIMINARY AMENDMENT
U.S. Appln. No. 09/773,736

Q62542

REMARKS

Preliminary Amendment

The compounds encompassed within new claims 30-36 are a subgroup of the compounds encompassed within claim 1, and the substituents recited in the new claims are specifically recited in claim 4. Furthermore, the substituents recited in these new claims are stated in the specification as being substituents of preferred compounds (page 15, lines 4-19).

The compound of new claims 37-43 is found in the specification at page 41, lines 11-12.

No new matter has been added; entry and consideration of this Amendment are respectfully requested.

Election of Species Requirement

As set forth in the Office Action, the Examiner has identified the instant application as allegedly containing claims directed to a plurality of disclosed patentably distinct species comprising the species disclosed in the specification.

The Examiner has required Applicants to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted.

In response to the Examiner's requirement, Applicants elect the following species for examination, with traverse:

4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-4-methylthiazole-5-carboxanilide.

This compound is shown in Example 1 of the specification, and recited in new claims 37-43.

RESPONSE TO ELECTION OF SPECIES REQUIREMENT
AND PRELIMINARY AMENDMENT
U.S. Appln. No. 09/773,736

Q62542

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Drew Hissong
Registration No. 44,765

SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: July 8, 2002

APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

The claims have been amended as follows:

22. (Twice amended) The method according to claims ~~claim~~-21, 32, or 39, wherein said disease associated with calcium release-activated calcium channels is a disease associated with IL-2 production.

23. (Twice amended) The method according to claims ~~claim~~-21, 32, or 39, wherein said disease associated with calcium release-activated calcium channels is an allergic, inflammatory or autoimmune disease.

24. (Twice amended) The method according to claims ~~claim~~-21, 32, or 39, wherein said disease associated with calcium release-activated calcium channels is bronchial asthma.

25. (Twice amended) The method according to claims ~~claim~~-21, 32, or 39, wherein said disease associated with calcium release-activated calcium channels is rheumatoid arthritis.

Claims 30-43 are added as new claims.